pxcl Value Investors: Is This Cheap Stock a Massive Bargain

Morrissgob

Zqfi Will Sporting Events Bring Customers Back to Cineplex Inc.
The shares of Teck Resources  TSX:TECK.B  NYSE:TECK  rose sha stanley cup rply by over 23% in September against a 1.8% drop in the TSX Composite Index. It was the second consecutive month its stock surged. In August, the Canadian miner   stock went up by 11%.What triggered a rally in Teck Resources stock Like the most other metal mining compan stanley cup ies, Teck Resources started 2020 on a negative note, as the fears of a sharp decline in metal demand  due to the COVID-19 pandemic  haunted investors. The company   stock shed 53% in the first quarter.Nonetheless, it has risen sharply in the last couple of quarters, as rallying base metal prices could help it boost profitability in the coming quarters. Copper prices skyrocketed in the last few months and reached their two-year high last week. As a result, Teck resources stock rose by 33% stanley cup  and 32% in the second and third quarters, respectively.On a year-to-date basis, the stock is still down by 17.4% and has a $9.8 billion market cap.It Svrj Worried About a Market Crash  Buy This Dividend-Growth Stock for Protection
Not all of the companies on the market a stanley cup re going to be a screaming buy for investors. It   not uncommon for  stanley cup companies to undergo turnaround plans to reinvent  stanley thermos mug themselves and usher in a new era of profitability.Often those turnaround candidates can represent an intriguing an opportunity for investors to buy in at a highly discounted price and reap the rewards once the stock recovers; at other times, the investment is simply not justified, at least in the short term.Here are several investments that fit into that latter classification.Bausch Health Companies  TSX:BHC  NYSE:BHC  is a pharmaceutical company with a troubled past and an uncertain future.Under its former name, Bausch was considered the darling of the market just a few years ago, aggressively expanding through acquisitions paid for by cheap loans. With each passing acquisition, Bausch was hiking drug rates and then moving to its next target.The plan worked fine until those cheap loans started to come due, and concerns ove